A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Rayamajhi, Ajit ^a,b,c   Nightingale, Sam ^a   Bhatta, Nisha Keshary ^d   Singh, Rupa ^d   Ledger, Elizabeth ^a   Bista, Krishna Prasad ^c   Lewthwaite, Penny ^a   Mahaseth, Chandeshwar ^b,c   Turtle, Lance ^a   Robinson, Jaimie Sue ^e   Galbraith, Sareen Elizabeth ^f   Wnek, Malgorzata ^a   Johnson, Barbara Wilmot ^e   Faragher, Brian ^g   Griffiths, Michael John ^a,h   Solomon, Tom ^a,i,j,k  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b National Academy of Medical Sciences   (Nepal)

^c Kanti Children's Hospital   (Nepal)

^d B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^e NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^f LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^g LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^h ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

ⁱ THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^j National Consortium for Zoonosis Research   (United Kingdom)

^k The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; DEXAMETHASONE; IMMUNOGLOBULIN; INTERLEUKIN 4; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PLACEBO; ANTIINFLAMMATORY AGENT;

ANTIBODY TITER; ARTICLE; CHILD; CHILD DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; JAPANESE ENCEPHALITIS; MALE; MELENA; MULTICENTER STUDY; NEPAL; OUTCOME ASSESSMENT; PILOT STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; VOMITING; BLOOD; CLINICAL TRIAL; ENCEPHALITIS, JAPANESE; IMMUNOLOGY; INFANT; JAPANESE ENCEPHALITIS VIRUS; PATHOLOGY; PLACEBO EFFECT; PRESCHOOL CHILD; TREATMENT OUTCOME;

ANIMALIA; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; WEST NILE VIRUS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DOUBLE-BLIND METHOD; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INTERLEUKIN-4; INTERLEUKIN-6; MALE; NEPAL; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 84928911141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122608     Document Type: Article

References (80)

1. Solomon T, Cardosa MJ. Emerging arboviral encephalitis. Newsworthy in the West but much more common in the East. BMJ. 2000; 321(7275):1484-5. Epub 2000/12/16. PubMed PMID: 11118162; PubMed Central PMCID: PMC1119205.
2. Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000; 68(4):405-15. Epub 2000/03/23. PubMed PMID: 10727474; PubMed Central PMCID: PMC1736874.
3. Solomon T, Dung NM, Kneen R, Thao le TT, Gainsborough M, Nisalak A, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain: a journal of neurology. 2002;125(Pt 5):1084-93. Epub 2002/04/19. PubMed PMID: 11960897.
4. Solomon T. Control of Japanese encephalitis-within our grasp? The New England journal of medicine. 2006; 355(9):869-71. Epub 2006/09/01. doi: 10.1056/NEJMp058263. PubMed PMID: 16943399.
5. Griffin DE. Immune responses to RNA-virus infections of the CNS. Nature reviews Immunology. 2003; 3(6):493-502. Epub 2003/05/31. doi: 10.1038/nri1105. PubMed PMID: 12776209.
6. Irani DN. Central nervous system inflammation: can't live with it, can't live without it. Current opinion in neurology. 2001; 14(3):347-8. Epub 2001/05/24. PubMed PMID: 11371758.
7. Kimura T, Griffin DE. Extensive immune-mediated hippocampal damage in mice surviving infection with neuroadapted Sindbis virus. Virology. 2003; 311(1):28-39. Epub 2003/07/02. PubMed PMID: 12832200.
8. German AC, Myint KS, Mai NT, Pomeroy I, Phu NH, Tzartos J, et al. A preliminary neuropathological study of Japanese encephalitis in humans and a mouse model. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2006; 100(12):1135-45. Epub 2006/07/04. doi: 10.1016/j.trstmh.2006.02.008. PubMed PMID: 16814333.
9. Johnson RT, Burke DS, Elwell M, Leake CJ, Nisalak A, Hoke CH, et al. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol. 1985; 18(5):567-73. Epub 1985/11/01. doi: 10.1002/ana.410180510. PubMed PMID: 3000282.
10. Li ZS, Hong SF, Gong NL. Immunohistochemical study on Japanese B encephalitis. Chin Med J (Engl). 1988; 101(10):768-71. Epub 1988/10/01. PubMed PMID: 2855049.
11. Miyake M. The pathology of Japanese encephalitis. Bulletin of the World Health Organization. 1964; 30:153-60. PMID: 14153404
12. Solomon T. Flavivirus encephalitis. The New England journal of medicine. 2004; 351(4):370-8. Epub 2004/07/23. doi: 10.1056/NEJMra030476. PubMed PMID: 15269317.
13. Solomon T, Kneen R, Dung NM, Khanh VC, Thuy TT, Ha DQ, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet. 1998; 351(9109):1094-7. Epub 1998/07/11. S0140-6736(97)07509-0 [pii] doi: 10.1016/S0140-6736(97)07509-0. PubMed PMID: 9660579.
14. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol. 2003; 35(1):33-42. Epub 2003/02/19. S0928824402004248 [pii]. PubMed PMID: 12589955.
15. Liu T, Chambers TJ. Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J Virol. 2001; 75(5):2107-18. Epub 2001/02/13. doi: 10.1128/JVI.75.5.2107-2118.2001. PubMed PMID: 11160715; PubMed Central PMCID: PMC114795.
16. Wang Y, Lobigs M, Lee E, Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol. 2003; 77(24):13323-34. Epub 2003/12/04. PubMed PMID: 14645588; PubMed Central PMCID: PMC296062.
17. Caramello P, Canta F, Balbiano R, Lipani F, Ariaudo S, De Agostini M, et al. Role of intravenous immunoglobulin administration in Japanese encephalitis. Clin Infect Dis. 2006; 43(12):1620-1. Epub 2006/11/17. CID40837 [pii] doi: 10.1086/509644. PubMed PMID: 17109300.
18. Burkes EJ Jr., Hoke J, Gomes E, Wolbarsht M. Wet versus dry enamel ablation by Er:YAG laser. J Prosthet Dent. 1992; 67(6):847-51. Epub 1992/06/11. PubMed PMID: 1403876.
19. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003; 361(9360):821-6. PubMed ISI:000181466600011. PMID: 12642049
20. Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009; 48(4):400-6. Epub 2009/01/16. doi: 10.1086/596309. PubMed PMID: 19143532.
21. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. The Journal of infectious diseases. 2003; 188(1):1- 4. Epub 2003/06/26. doi: 10.1086/376871. PubMed PMID: 12825164.
22. Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bull World Health Organ. 1995; 73(2):237-44. Epub 1995/01/01. PubMed PMID: 7743596; PubMed Central PMCID: PMC2486759
23. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003; 361(9360):821-6. Epub 2003/03/19. PubMed PMID: 12642049.
24. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. The Journal of infectious diseases. 2003; 188(1):5-12. Epub 2003/06/26. doi: 10.1086/376870. PubMed PMID: 12825165.
25. Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immun. 2002; 9(3):544-9. doi: 10.1128/Cdli.9.3.544-549.2002. PubMed ISI:000175713100006. PMID: 11986257
26. Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol. 2000; 38(5):1823-6. PubMed ISI:000086902400023. PMID: 10790107
27. Johnson AJ, Martin DA, Karabatsos N, Roehrig JT. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin Microbiol. 2000; 38(5):1827-31. PubMed ISI:000086902400024. PMID: 10790108
28. Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, Guirakhoo F, et al. Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests. Clin Vaccine Immunol. 2009; 16(7):1052-9. doi: 10.1128/Cvi.00095-09. PubMed ISI:000267747700014. PMID: 19458204
29. Rayamajhi A, Ansari I, Ledger E, Bista KP, Impoinvil DE, Nightingale S, et al. Clinical and prognostic features among children with acute encephalitis syndrome in Nepal; a retrospective study. Bmc Infect Dis. 2011; 11. Artn 294 doi: 10.1186/1471-2334-11-294. PubMed ISI:000297115800001.
30. Rayamajhi A, Singh R, Prasad R, Khanal B, Singhi S. Clinico-laboratory profile and outcome of Japanese encephalitis in Nepali children. Annals of Tropical Paediatrics. 2006; 26(4):293-301. doi: 10.1179/146532806x152818. PubMed ISI:000242714600004. PMID: 17132294
31. Lewthwaite P, Begum A, Ooi MH, Faragher B, Lai BF, Sandaradura I, et al. Disability after encephalitis: development and validation of a new outcome score. B World Health Organ. 2010; 88(8):584-92. doi: 10.2471/Blt.09.071357. PubMed ISI:000280867900008. PMID: 20680123
32. Kneen R, Solomon T, Appleton R. The role of lumbar puncture in suspected CNS infection - a disappearing skill? Arch Dis Child. 2002; 87(3):181-3. PubMed ISI:000177770700004. PMID: 12193421
33. Parida M, Dash PK, Tripathi NK, Sannarangaiah AS, Saxena P, Agarwal S, et al. Japanese encephalitis outbreak, India, 2005. Emerging Infectious Diseases. 2006; 12(9):1427-30. PubMed ISI:000240081400019. PMID: 17073095
34. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. B World Health Organ. 2011; 89(10):766-74. doi: 10.2471/Blt.10.085233. PubMed ISI:000295707700015. PMID: 22084515
35. Bista MB, Shrestha JM. Epidemiological situation of Japanese encephalitis in Nepal. JNMAJ NepalMed Assoc. 2005; 44:51-6. PMID: 16554872
36. Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet. 2001; 358(9284):791-5. PubMed PMID: 11564484.
37. Tandan JB, Ohrr H, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization. Vaccine. 2007;ePUB.
38. Pant GR. A serological survey of pigs, horses, and ducks in Nepal for evidence of infection with Japanese encephalitis virus. Ann N Y Acad Sci. 2006; 1081:124-9. Epub 2006/12/01. 1081/1/124 [pii] doi: 10.1196/annals.1373.013. PubMed PMID: 17135501.
39. Lang TA, White NJ, Tran HT, Farrar JJ, Day NP, Fitzpatrick R, et al. Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS neglected tropical diseases. 2010; 4(6):e619. Epub 2010/07/09. doi: 10.1371/journal.pntd.0000619. PubMed PMID: 20614013; PubMed Central PMCID: PMC2894123.
40. Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol. 1988; 141(10):3606-10. Epub 1988/11/15. PubMed PMID: 2460542.
41. Zhang MJ, Wang MJ, Jiang SZ, Ma WY. Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies. Journal of medical virology. 1989; 29(2):133-8. Epub 1989/10/01. PubMed PMID: 2557383.
42. Gupta AK, Lad VJ, Koshy AA. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies. Acta virologica. 2003; 47(3):141-5. Epub 2003/12/09. PubMed PMID: 14658841.
43. Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine. 2003; 21(25-26):3675-83. Epub 2003/08/19. PubMed PMID: 12922097.
44. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. Journal of virology. 2003; 77(4):2578-86. Epub 2003/01/29. PubMed PMID: 12551996; PubMed Central PMCID: PMC141119.
45. Ben-Nathan D, Gershoni-Yahalom O, Samina I, Khinich Y, Nur I, Laub O, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. Bmc Infect Dis. 2009; 9:18. Epub 2009/02/19. doi: 10.1186/1471-2334-9-18. PubMed PMID: 19222853; PubMed Central PMCID: PMC2660335.
46. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. Journal of virology. 2003; 77(24):12941-9. Epub 2003/12/04. PubMed PMID: 14645550; PubMed Central PMCID: PMC296058.
47. Morrey JD, Siddharthan V, Olsen AL, Roper GY, Wang H, Baldwin TJ, et al. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis. 2006; 194(9):1300-8. Epub 2006/10/17. JID36675 [pii] doi: 10.1086/508293. PubMed PMID: 17041857.
48. Morrey JD, Siddharthan V, Olsen AL, Wang H, Julander JG, Hall JO, et al. Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrobial agents and chemotherapy. 2007; 51(7):2396-402. Epub 2007/04/25. doi: 10.1128/AAC.00147-07. PubMed PMID: 17452485; PubMed Central PMCID: PMC1913249.
49. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature medicine. 2010; 16(10):1117-9. Epub 2010/10/05. doi: 10.1038/nm.2233. PubMed PMID: 20890292; PubMed Central PMCID: PMC2952052.
50. DejnirattisaiW, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745-8. Epub 2010/05/08. doi: 10.1126/science.1185181. PubMed PMID: 20448183.
51. Kluger G, Schottler A, Waldvogel K, Nadal D, Hinrichs W, Wundisch GF, et al. Tickborne encephalitis despite specific immunoglobulin prophylaxis. Lancet. 1995; 346(8988):1502. Epub 1995/12/02. PubMed PMID: 7491037.
52. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia. 2007; 55(5):483-96. Epub 2007/01/05. doi: 10.1002/glia.20474. PubMed PMID: 17203475.
53. Chen CJ, Chen JH, Chen SY, Liao SL, Raung SL. Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol. 2004; 78(22):12107-19. Epub 2004/10/28. 78/22/12107 [pii] doi: 10.1128/JVI.78.22.12107-12119.2004. PubMed PMID: 15507597; PubMed Central PMCID: PMC525064.
54. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol. 1999; 100(1-2):124-39. Epub 2000/03/01. S0165572899001873 [pii]. PubMed PMID: 10695723.
55. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989; 19(4):689-94. Epub 1989/04/01. doi: 10.1002/eji.1830190418. PubMed PMID: 2543584.
56. Morris MM, Dyson H, Baker D, Harbige LS, Fazakerley JK, Amor S. Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. J Neuroimmunol. 1997; 74(1-2):185-97. Epub 1997/04/01. S0165-5728(96)00786-2 [pii]. PubMed PMID: 9119972.
57. Brett FM, Mizisin AP, Powell HC, Campbell IL. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol. 1995; 54(6):766-75. PubMed PMID: 7595649.
58. Paul R, Koedel U, Winkler F, Kieseier BC, Fontana A, Kopf M, et al. Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain. 2003; 126(Pt 8):1873-82. PubMed PMID: 12821529.
59. Abraham CS, Deli MA, Joo F, Megyeri P, Torpier G. Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. Neurosci Lett. 1996; 208(2):85-8. PubMed PMID: 8859896.
60. Munoz-Fernandez MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol. 1998; 56(3):307-40. Epub 1998/10/14. S0301008298000458 [pii]. PubMed PMID: 9770242.
61. Winter PM, Dung NM, Loan HT, Kneen R, Wills B, Thu le T, et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis. 2004; 190(9):1618-26. Epub 2004/10/13. JID32574 [pii] doi: 10.1086/423328. PubMed PMID: 15478067.
62. Wang SM, Lei HY, Huang MC, Su LY, Lin HC, Yu CK, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2006; 37(1):47-52. Epub 2006/07/25. doi: 10.1016/j.jcv.2006.05.009. PubMed PMID: 16861032.
63. Reske D, Thomas AV, Petereit HF, Fink GR, Schroeter M. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors. Neuroimmunomodulation. 2009; 16(6):385-91. Epub 2009/07/18. doi: 10.1159/000228913. PubMed PMID: 19609087.
64. Pigard N, Elovaara I, Kuusisto H, Paalavuo R, Dastidar P, Zimmermann K, et al. Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. Journal of neuroimmunology. 2009; 209(1-2):114-20. Epub 2009/02/17. doi: 10.1016/j.jneuroim.2009.01.014. PubMed PMID: 19217671.
65. Wu KH, Wu WM, Lu MY, Chiang BL. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2006; 17(1):60-8. Epub 2006/01/24. doi:10.1111/j.1399-3038.2005.00344.x. PubMed PMID: 16426257.
66. Tawfik DS, Cowan KR, Walsh AM, Hamilton WS, Goldman FD. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2012; 23(1):88-95. Epub 2011/01/27. doi: 10.1111/j.1399-3038.2010.01129.x. PubMed PMID: 21265884.
67. Ibanez C, Sune P, Fierro A, Rodriguez S, Lopez M, Alvarez A, et al. Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia. Bio-Drugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2005; 19(1):59-65. Epub 2005/02/05. PubMed PMID: 15691218.
68. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994; 84(7):2136-43. Epub 1994/10/01. PubMed PMID: 7919327.
69. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood. 2002; 100(5):1774-9. Epub 2002/08/15. PubMed PMID: 12176899.
70. Jolles S, Hughes J, Rustin M. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. Journal of the American Academy of Dermatology. 1999; 40(1):121-3. Epub 1999/01/28. PubMed PMID: 9922029.
71. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol. 1987; 5:429-59. Epub 1987/01/01. doi: 10.1146/annurev.iy.05.040187.002241. PubMed PMID: 3297106.
72. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990; 8:253-78. Epub 1990/01/01. doi: 10.1146/annurev.iy.08.040190.001345. PubMed PMID: 2188664.
73. Ling ZD, Ziltener HJ, Webb BT, Matheson DS. Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cellular immunology. 1990; 129(1):95-103. Epub 1990/08/01. PubMed PMID: 2364444.
74. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. The Journal of clinical investigation. 1993; 92(5):2533-9. Epub 1993/11/01. doi: 10.1172/JCI116862. PubMed PMID: 8227366; PubMed Central PMCID: PMC288439.
75. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993; 341(8848):789-90. Epub 1993/03/27. PubMed PMID: 8096001.
76. Llaurado G, Ceperuelo-Mallafre V, Vilardell C, Simo R, Freixenet N, Vendrell J, et al. Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: a potential role of low-grade inflammation. Diabetes care. 2012; 35(5):1083-9. Epub 2012/02/24. doi: 10.2337/dc11-1475. PubMed PMID: 22357186; PubMed Central PMCID: PMC3329819.
77. Kneen R, Michael BD, Menson E, Mehta B, Easton A, Hemingway C, et al. Management of suspected viral encephalitis in children - Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group national guidelines. J Infect. 2012; 64(5):449-77. Epub 2011/11/29. S0163-4453(11)00562-7 [pii]doi: 10.1016/j.jinf.2011.11.013. PubMed PMID: 22120594.
78. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. The Lancet infectious diseases. 2010; 10(12):835-44. Epub 2010/10/19. doi: 10.1016/S1473-3099(10)70222-X. PubMed PMID: 20952256.
79. Ramakrishna C, Newo AN, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS pathogens. 2011; 7(6):e1002071. Epub 2011/06/10. doi: 10.1371/journal.ppat.1002071. PubMed PMID: 21655109; PubMed Central PMCID: PMC3107211.
80. Le VT, Phan TQ, Do QH, Nguyen BH, Lam QB, Bach VC, et al. Viral etiology of encephalitis in children in southern Vietnam: results of a one-year prospective descriptive study. PLoS neglected tropical diseases. 2010; 4(10):e854. Epub 2010/11/05. doi: 10.1371/journal.pntd.0000854. PubMed PMID: 21049060; PubMed Central PMCID: PMC2964288.